Remember when Moderna Inc. (MRNA) was the darling of the biotech world? The Massachusetts-based company that became a household name during the COVID-19 pandemic has had a rough few years, watching its stock crater nearly 92% from its 2021 all-time high. But something interesting is happening now. The stock is showing signs of life again, and investors are paying attention.
Moderna Stages a Comeback: Momentum Surges After Strong Revenue Guidance

Get Moderna Alerts
Weekly insights + SMS alerts
A Sharp Turnaround in Momentum
Here's where things get interesting. Moderna's momentum score, which tracks price movements and volatility across multiple timeframes, rocketed from 22.5 to 74.61 in just one week. That's not a typo. This kind of shift reflects a genuine change in how investors view the stock.
The numbers back it up. Shares have surged 76% from their November 2025 lows. The rally hasn't lost steam either, with the stock climbing 31.7% over the past month and tacking on another 14.8% in the past week alone. For a company that spent years in the penalty box, this is quite the comeback attempt.
Better Guidance Fuels the Rally
What's driving the turnaround? Moderna delivered better-than-expected guidance for full-year 2025. The company now projects revenue of $1.9 billion, roughly $100 million above the midpoint it provided during its third-quarter earnings call. That's a meaningful beat for a company trying to prove it has life beyond its COVID franchise.
The financial picture improved on multiple fronts. Moderna lowered its GAAP operating expense forecast by approximately $200 million for the year, showing some discipline on the cost side. Perhaps most importantly, the company increased its projected year-end cash balance to $8.1 billion. That's real money, and it gives Moderna runway to invest in its pipeline without immediately panicking about liquidity.
All of these tailwinds have aligned to create significant optimism around what had been a severely beaten-down stock. On Thursday, shares closed at $39.36, down 3.01%, but ticked up 0.66% in overnight trading. The stock now scores high on momentum metrics, showing favorable price trends across short, medium, and long-term horizons.
Whether this rally has legs or fizzles out remains to be seen, but for now, Moderna is reminding investors why momentum matters in biotech.
More News

Microsoft and Stellantis Are Building 100 AI Tools for Your Car. Here's What That Means.
Circle April 20th on your calendar

Schwab's Record Quarter Meets Crypto Rollout, But Stock Takes a Dive

PayPal's Rough Ride: Lawsuits, Scrapped Targets, and a Venmo Bright Spot

A Senator's Magnificent Seven Shopping Spree: Why He's Betting on Microsoft and Nvidia in 2026

Trump's Executive Order 14330: What Wall Street Doesn't Want You to Know

Navitas Semiconductor Stock Surges 13% After Adding Broadcom Veteran to Board

TotalEnergies Stock Jumps on Strong First-Quarter Forecast
Get Moderna Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all news
Microsoft and Stellantis Are Building 100 AI Tools for Your Car. Here's What That Means.

Trump's Executive Order 14330: What Wall Street Doesn't Want You to Know (Ad)

Schwab's Record Quarter Meets Crypto Rollout, But Stock Takes a Dive

PayPal's Rough Ride: Lawsuits, Scrapped Targets, and a Venmo Bright Spot

A Senator's Magnificent Seven Shopping Spree: Why He's Betting on Microsoft and Nvidia in 2026
Mar-a-Lago Bombshell (Ad)

Navitas Semiconductor Stock Surges 13% After Adding Broadcom Veteran to Board





